Another original study from Hombach and Abken (Cologne, Germany) shows that CD4+CD25− but not CD4+CD25+ (T regulatory, Treg) were able to kill cancer cells [11] . The low cytotoxic activity of CAR-Treg allows use of these cells to inhibit autoimmune responses and treat chronic autoimmune diseases [11] . CAR-Treg cells can also be used for allogenic CAR-T cell generation without the risk of inducing graft-versus-host response.
Finally, the report from Golubovskaya et al. demonstrates a new CD47-CAR-T efficacy against ovarian, pancreatic, and hepatocellular carcinoma, as well as lung cancer and melanoma [12] . The authors used mouse and humanized CD47-CAR-T cells, which effectively killed CD47+ cancer cells but not CD47− cells. The efficacy of CD47-CAR-T cells was significantly higher than Mock CAR-T cells in a pancreatic BxPC3 xenograft NSG mice model [12] .
In summary, this issue demonstrates original and novel approaches of CAR-T cells against different types of tumors, e.g., glioblastoma, head and neck, colorectal hepatic metastases, pancreatic, and mesothelioma; demonstrates original CAR-T cells targeting several tumor-associated antigens (EGFR1, Her2, Her3 and Her-4), increasing the efficacy of CAR-T cell therapy; demonstrates novel CAR-CD4+CD25− and CD4+CD25+ T reg cells and highlights their functional differences; and shows novel CD47-CAR-T cells and regional delivery of CAR-T cells in solid tumors. The original view on quality of life analyses in clinical trial design proposed by Dr. Grace Dy et al. group could increase the safety and the outcome of Phase I clinical trials. Future novel CAR-T cells findings will be discussed in the next CAR-T issue in 2018.
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